Vallon Pharmaceuticals to Present at the H.C. Wainwright BioConnect Conference
Vallon Pharmaceuticals (NASDAQ: VLON) announced that CEO David Baker will present at the H.C. Wainwright BioConnect Conference from January 10-13, 2022. This virtual event will feature a video webcast available on-demand starting January 10, 2022. Vallon focuses on developing innovative drugs for CNS disorders, with its lead product ADAIR targeting ADHD and narcolepsy.
- None.
- None.
PHILADELPHIA, PA, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of central nervous system (CNS) disorders, announced today that David Baker, President & Chief Executive Officer of Vallon will present at the virtual H.C. Wainwright BioConnect Conference, taking place January 10-13, 2022.
A video webcast of the presentation will be available for viewing on-demand beginning Monday, January 10, 2022, at 7:00 AM ET for those registered for the event and will be accessible on the Events page of the Investors section of the Company's website (www.vallon-pharma.com) and will be archived for 90 days following the event.
About Vallon Pharmaceuticals, Inc.
Vallon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, headquartered in Philadelphia, PA. The Company is focused on the development of new medications to help patients with CNS disorders. The Company’s lead investigational product candidate, ADAIR, is a novel abuse deterrent formulation of amphetamine immediate release being developed for the treatment of ADHD and narcolepsy.
For more information about the company, please visit www.vallon-pharma.com or connect with us on LinkedIn or Twitter.
References and links to websites have been provided for convenience, and the information contained on any such website is not a part of, or incorporated by reference into, this press release. Vallon is not responsible for the contents of third-party websites.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
vallon@jtcir.com
FAQ
What is the H.C. Wainwright BioConnect Conference 2022 regarding Vallon Pharmaceuticals?
Where can I view the Vallon Pharmaceuticals conference presentation?
What is Vallon Pharmaceuticals' lead product candidate?
What does Vallon Pharmaceuticals focus on?
